Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

• Molderings Gerhard J.

  Institute of Human Genetics, University Hospital of Bonn, Germany

• Raithel Martin

  Universitätsklinikum Erlangen, Medizinische Klinik, Germany

• Kratz Felix

  Tumor Biology Center, Germany

• Azemar Marc

  Tumor Biology Center, Germany

• Haenisch Britta

  Institute of Human Genetics, University Hospital of Bonn, Germany

• Harzer Sabrina

  Institute of Human Genetics, University Hospital of Bonn, Germany

• Homann Jürgen

  Evangelische Kliniken Bonn, Germany

抄録

We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.<br>

収録刊行物

• Internal Medicine

  Internal Medicine 50 (6), 611-615, 2011

  一般社団法人 日本内科学会

キーワード

• systemic mastocytosis
• omalizumab
• tryptase

詳細情報

• CRID: 1390001204871133184
• NII論文ID: 130000649895
• DOI: 10.2169/internalmedicine.50.4640
• ISSN: 13497235
• ISSN: 09182918
• Web Site: http://www.jstage.jst.go.jp/article/internalmedicine/50/6/50_6_611/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012013323
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可